Human Vaccines & Immunotherapeutics(formerly Human Vaccines)
Volume 8, Issue 8  August 2012
http://www.landesbioscience.com/journals/vaccines/toc/volume/8/issue/7/

Cancer Commentary Series
SPECIAL FOCUS COMMENTARIES
Overview of the cancer vaccine field: Are we moving forward?
Alex Kudrin and Michael G. Hanna, Jr
http://dx.doi.org/10.4161/hv.20474
Abstract | Full Text | PDF

Biological heterogeneity of cancer: Implication to therapy
Isaiah J. Fidler
http://dx.doi.org/10.4161/hv.19643
Abstract | Full Text | PDF

Inter-tumor heterogeneity
Mike Cusnir and Ludmila Cavalcante
Abstract | Full Text

A tale of two pities: Autologous melanoma vaccines on the brink
David Berd
http://dx.doi.org/10.4161/hv.20923
Abstract | Full Text | PDF

Challenges in the development of an autologous heat shock protein based anti-tumor vaccine
Dirk J. Reitsma and Austin J. Combest
Abstract | Full Text

Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer
Michael G. Hanna, Jr
http://dx.doi.org/10.4161/hv.20740
Abstract | Full Text | PDF

Open Access Article
Cancer Vaccines: Are We There Yet?
Michael G. Hanna, Jr
http://dx.doi.org/10.4161/hv.21660

Abstract:
For nearly two decades there has been an abundance of research and clinical development programs underway to develop active specific immunotherapies, to educate the patient’s immune response, specifically the T-cell immunity and memory, to recognize and destroy tumor cells by cell-mediated cellular toxicity. While many of these technology platforms achieved promising results in preclinical and clinical phase I and II clinical trials, essentially all but one have failed to achieve FDA market approval as a therapeutic drug product.